What is HC Wainwright’s Forecast for Alumis Q3 Earnings?

Alumis Inc. (NASDAQ:ALMS) – Stock analysts at HC Wainwright issued their Q3 2024 EPS estimates for Alumis in a report released on Thursday, October 17th. HC Wainwright analyst M. Kapoor anticipates that the company will earn ($2.27) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Alumis’ current full-year earnings is ($6.86) per share. HC Wainwright also issued estimates for Alumis’ Q4 2024 earnings at ($1.20) EPS, FY2024 earnings at ($11.42) EPS, Q1 2025 earnings at ($1.21) EPS, Q2 2025 earnings at ($1.22) EPS, Q3 2025 earnings at ($1.23) EPS, Q4 2025 earnings at ($1.24) EPS and FY2025 earnings at ($4.90) EPS.

ALMS has been the subject of a number of other research reports. Morgan Stanley assumed coverage on shares of Alumis in a research note on Tuesday, July 23rd. They set an “overweight” rating and a $36.00 price target for the company. Leerink Partnrs raised shares of Alumis to a “strong-buy” rating in a research report on Tuesday, July 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alumis in a research report on Monday, August 19th. Leerink Partners began coverage on Alumis in a research note on Tuesday, July 23rd. They set an “outperform” rating and a $29.00 price target for the company. Finally, Guggenheim started coverage on Alumis in a research note on Tuesday, July 23rd. They issued a “buy” rating and a $32.00 price objective for the company. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $28.00.

Alumis Stock Up 4.6 %

NASDAQ ALMS opened at $12.58 on Monday. Alumis has a 52 week low of $9.54 and a 52 week high of $13.53. The firm’s 50 day moving average price is $11.65.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($23.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.57) by ($21.53).

Institutional Investors Weigh In On Alumis

A number of institutional investors have recently added to or reduced their stakes in the company. SR One Capital Management LP bought a new position in shares of Alumis during the 2nd quarter worth approximately $26,067,000. Yu Fan bought a new stake in Alumis during the second quarter worth $10,502,000. Ally Bridge Group NY LLC purchased a new position in Alumis in the second quarter worth $8,229,000. Towerview LLC bought a new position in Alumis in the 2nd quarter valued at $4,123,000. Finally, Millennium Management LLC purchased a new stake in shares of Alumis during the 2nd quarter valued at $3,376,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.